The development of the lymphocyte genome sensitivity (LGS) test for the diagnosis of cancer
Oncascan is introducing a step change in cancer diagnosis and management. The patented Lymphocyte Genome Sensitivity (LGS) blood test uses increased sensitivity to ultra-violet induced DNA damage of lymphocytes from cancer patients to distinguish between those with and without the disease.
The project aims to develop a practical system for use in clinical laboratories to improve the management of patients with suspected cancers. Before embarking on invasive and costly investigations, patients found to not have cancer can be identified with the obvious reduction for them in anxiety, discomfort, time off work and clinical risk.